Fulgent Genetics Names Linda Marsh to Board of Directors
August 05 2019 - 8:00AM
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”,
“Fulgent” or the “company”) today announced the addition of Linda
Marsh, Senior Executive Vice President of AHMC Healthcare, Inc. to
its board of directors, effective August 1.
“We’re honored to welcome Ms. Marsh to our Board of Directors,”
said Ming Hsieh, Chairman and Chief Executive Officer of Fulgent
Genetics. “Her knowledge and expertise in the healthcare industry,
government relations and reimbursement will bring invaluable
insight to our Board of Directors, and to Fulgent Genetics as a
whole. We look forward to the contributions that Ms. Marsh will add
to our organization as we deliver our next generation sequencing
capabilities to our growing customer base.”
“I am excited to be joining Fulgent Genetics’ Board of
Directors,” said Ms. Linda Marsh. “I admire Fulgent for its
technology platform, built to deliver next generation sequencing
capabilities to hospitals, clinics and research organizations. I am
pleased to have the opportunity to work with fellow Board members
and management as the company strives to achieve its goals.”
Ms. Marsh has been a member of the Board of Directors of Apollo
Medical Holdings, Inc. since January 2019, and she is currently the
Senior Executive Vice President of AHMC Healthcare Inc. (“AHMC
Healthcare”), a fully-integrated hospital health system in Southern
California with over 1,200 acute care beds and over 7,000
employees. She joined AHMC Healthcare in 1999 and oversees all
financial matters for seven acute care hospitals: San Gabriel
Valley Medical Center, Garfield Medical Center, Anaheim Regional
Medical Center, Whittier Hospital Medical Center, Alhambra
Hospital, Monterey Park Hospital and Greater El Monte Community
Hospital. Additionally, Ms. Marsh is responsible for all federal,
state and local government relations, as well as all risk
management activities. Ms. Marsh is a Board member of the Hospital
Association of Southern California, a Board member of Private
Essential Access Community Hospitals and also a Board member of the
American Red Cross. She is also an active member in the Healthcare
Financial Management Association. In addition, she chairs or is a
participating member of numerous hospital governing boards,
hospital committees and community organizations. Ms. Marsh received
a Bachelor of Science degree in Economics and a Master’s degree in
Accounting from the University of Southern California. She also
completed a Healthcare Executive Program at the University of
Colorado.
About Fulgent Genetics
Fulgent Genetics is a technology company with a focus on
offering comprehensive genetic testing to provide physicians with
clinically actionable diagnostic information they can use to
improve the quality of patient care. The company has developed a
proprietary technology platform that allows it to offer a broad and
flexible test menu and continually expand and improve its
proprietary genetic reference library, while maintaining accessible
pricing, high accuracy and competitive turnaround times. The
company believes its test menu offers more genes for testing than
its competitors in today’s market, which enables it to provide
expansive options for test customization and clinically actionable
results.
Investor Relations Contact:The Blueshirt
GroupNicole Borsje, 415-217-2633, nborsje@blueshirtgroup.com
Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart
From Apr 2023 to Apr 2024